ArticleBMC gastroenterology2026
Dramatic regression of mass-forming gastric IgG4-related disease with inebilizumab: a case report.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric immunoglobulin G4-related disease (IgG4-RD) is exceedingly rare, with fewer than 50 cases reported worldwide. Its mass-forming presentation frequently mimics malignancy, leading to high rates of unnecessary surgical resection. Inebilizumab, a CD19-directed monoclonal antibody and the first FDA-approved therapy for IgG4-RD, has not previously been described in gastric IgG4-RD. We report the first case of mass-forming gastric IgG4-RD treated with inebilizumab, achieving clinical, endoscopic, and histologic remission without surgical intervention. CASE PRESENTATION: A 52-year-old man with chronic hypereosinophilia, nonischemic cardiomyopathy, and multisystem inflammatory disease presented with symptomatic anemia and a 2 cm gastric antral mass identified on CT imaging. Endoscopy revealed an antral mass, highly suspicious for malignancy. Initial biopsies showed Helicobacter pylori associated chronic active gastritis without definitive malignancy. Repeat sampling after H. pylori eradication demonstrated dense transmural lymphoplasmacytic and eosinophilic infiltration with 225 IgG4⁺ plasma cells per high-power field, an IgG4/IgG ratio of 37.5%, and a markedly elevated serum IgG4 of 1,245 mg/dL, establishing the diagnosis of gastric IgG4-RD. Concurrent lung biopsy confirmed multisystem involvement. The patient was initiated on inebilizumab. Within six weeks, follow-up endoscopy demonstrated significant resolution of the gastric mass with histologic remission (IgG4/IgG ratio < 10%), and six-month follow-up revealed near-complete resolution of the gastric abnormalities.
conclusionsThis case demonstrates that CD19-targeted B-cell depletion with inebilizumab can induce rapid, profound remission in gastric IgG4-RD, obviating the need for gastrectomy and chronic glucocorticoid therapy. These findings support early consideration of IgG4-RD in the differential diagnosis of mass-forming gastric lesions and highlight the transformative potential of mechanism-based therapy in this diagnostically challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.